Creative Medical Technology Holdings Announces MyeloCelz™ The Company's Second Regenerative Immunotherapy Product prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Creative Medical Technology Holdings, trading under Ticker Symbol CELZ, announced the filing of a provisional patent application in connection.
iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies
Anthony Japour, M.D., a seasonedbiotech and pharmaceutical executive with over 30 years of experience, appointed as Chief Executive Officer
Camillo Ricordi, M.D., one of the world s leading scientists in diabetes cure-focused research, cell transplantation and regenerative medicine, appointed as Chief Scientist
SAN MATEO, CA / ACCESSWIRE / June 9, 2021 / iTolerance, Inc
. ( iTolerance or the Company ), a biotechnology company focused on the development of innovative regenerative medicines, today announced the formation of its Executive Leadership Team with the hiring of Anthony Japour, M.D. as Chief Executive Officer and Camillo Ricordi, M.D. as Chief Scientist.
Internationally Renowned Clinician Scientist Camillo Ricordi Head of Diabetes Research Institute Joins Creative Medical Technology Holdings
Immunologist Surgeon who Invented Islet Transplantation to Assist Company in Advancing ImmCelz® Platform
News provided by
Share this article
Share this article
PHOENIX, May 20, 2021 /PRNewswire/ Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company s Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs Timothy Henry, Santosh Kesari, Ceagan Du, and Boris Reznik in accelerating advancement of its ImmCelz® Regenerative Immunotherapy platform. Currently the Company is engaged with the FDA regarding clearance of its IND # 27375 covering the use of ImmCelz® to treat stroke.
Vertex Pharmaceuticals Incorporated: Vertex gibt Erteilung des Fast-Track-Status durch die FDA und Start der klinischen Phase-1/2-Studie zu VX-880 bekannt finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.